Due to a recent agreement between Novartis and NHS England, an accelerated review for an injectable heart disease drug called Inclisiran will be conducted by the National Institute for Health and Care Excellence (NICE), which could see it be made available by 2021.
Inclisiran, which could be the first cholesterol-lowering treatment in the small-interfering class of RNA, will be tested in patients within the UK as part of a large-scale phase 3 clinical trial and is expected to begin before 2021.
“NICE to conduct an accelerated review on Inclisiran.“
The medicine will be used as a preventive complement to statin therapy for those diagnosed with cardiovascular disease, which could see the reduction of fifty-five thousand strokes and heart attacks per year, save thirty-five thousand lives in the next decade, and cut medical bills for those not taking statins.
Chair of NHS England, Lord David Prior, stated: “It is a great illustration of how the UK Life Sciences Strategy can help both NHS patients and the wider economy and shows that the UK can be the center of a dynamic life sciences ecosystem whilst delivering great care.”